On Monday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Navios Maritime Partners L.P. (NYSE:NMM), Dynavax Technologies Corporation (NASDAQ:DVAX), TrueCar, Inc. (NASDAQ:TRUE), Walter Energy, Inc. (NYSE:WLT)
Navios Maritime Partners L.P. (NYSE:NMM), with shares inclined 10.97%, closed at $10.82.
Dynavax Technologies Corporation (NASDAQ:DVAX), with shares jumped 10.79%, settled at $25.06, hitting new 52-week high of $25.49.
TrueCar, Inc. (NASDAQ:TRUE), with shares climbed 10.77%, and closed at $19.24.
Walter Energy, Inc. (NYSE:WLT), surged 10.14%, and closed at $0.63.
Latest NEWS regarding these Stocks are depicted underneath:
Navios Maritime Partners L.P. (NYSE:NMM)
On Monday, Navios Maritime Partners L.P. (NMM) shares continued to gain on the news that Deutsche Bank upgraded its rating to “buy” from “hold,” while maintaining its price target at $15.
Analysts said, “Our upgrade to ‘buy’ from ‘hold’ is opportunistic following the sharp sell-off in shares, which we view as the baby (Navios shares) being thrown out with bathwater (dry bulk) without regard for Navios’s unique investment points.”
Navios Maritime Partners L.P. owns and operates dry cargo vessels in Europe, Asia, North America, and Australia. It provides seaborne transportation services for a range of drybulk commodities that comprise iron ore, coal, grain, and fertilizers, in addition to charters its vessels under medium to long-term charters.
Dynavax Technologies Corporation (NASDAQ:DVAX)
Formerly, on 5th of this month, Dynavax Technologies Corporation (DVAX), stated financial results for the fourth quarter and year ended December 31, 2014.
The Corporation had $122.7 million in cash, cash equivalents and marketable securities as of December 31, 2014. Loss from operations of $91.3 million for the year ended December 31, 2014 raised by $24.8 million contrast to the year ended December 31, 2013 primarily as a result of expenses regarding conduct of clinical trials. A Phase 3 clinical trial of hepatitis B vaccine HEPLISAV-B™ (known as HBV-23) was initiated in the second quarter of 2014 and an independent Data and Safety Monitoring Board (DSMB) reviewed accessible data in early November 2014 and late February 2015 and recommended continuation of the trial without change. A Phase 1/2 study of SD-101 in combination with local radiation for the treatment of indolent lymphoma was initiated in the fourth quarter.
The net loss allocable to ordinary stockholders for the twelve months ended December 31, 2014 was $90.7 million, or $3.45 per basic and diluted share. The net loss allocable to ordinary stockholders for the twelve months ended December 31, 2013 was $75.2 million, or $3.83 per basic and diluted share, which comprises a one-time non-cash deemed dividend of $8.5 million related to the beneficial conversion feature of the Series B Convertible Preferred Stock.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical corporation, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.
TrueCar, Inc. (NASDAQ:TRUE)
Last week, on Monday, Mazda Motor Corp.’s CX-9 sport-utility vehicle, which sells at an average of 19 percent off the manufacturer’s suggested retail price (MSRP), tops the list of best savings on new vehicles in March, according to TrueCar, Inc. (TRUE), the negotiation-free car buying and selling mobile marketplace.
“Given that Japanese automakers want to hit annual sales targets as they close out their business year, consumers should expect to find excellent savings, even in the hot midsize utility segment,” said John Krafcik, president of TrueCar. “The push by Japanese brands spills over to the rest of the industry, which wants to grab the attention of in-market consumers, driving up overall sales volume.”
TrueCar, Inc. operates as an Internet-based information, technology, and communication services corporation. The corporation operates its platform on the TrueCar Website and TrueCar mobile applications.
Walter Energy, Inc. (NYSE:WLT)
Formerly, on 5th of this month, Walter Energy, Inc. (WLT), declared that the Corporation has been notified by the New York Stock Exchange that its ordinary stock does not presently satisfy one of the NYSE’s continued listing standards. The NYSE requires that the average closing price per share of a listed corporation’s ordinary stock be at least $1.00 over a successive 30 trading-day period. As of March 3, 2015, the average closing price per share of the Corporation’s ordinary stock over the preceding 30 trading-day period was $0.99.
Under the NYSE’s rules, the Corporation has six months to regain compliance with the NYSE’s continued listing standards. The Corporation’s ordinary stock will continue to be listed and traded on the NYSE during this period, subject to the Corporation’s compliance with other continued listing standards. As required by the NYSE’s rules, the Corporation plans to notify the NYSE within 10 business days of the receipt of the notice of non-compliance of its intent to cure the deficiency.
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry. It operates through two segments, U.S. Operations, and Canadian and U.K. Operations. The corporation also extracts, processes, markets, and/or possesses mineral reserves of thermal coal and anthracite coal, in addition to produces metallurgical coke and coal bed methane gas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
